How genetic diversity affects biological aging and Alzheimer's disease risk
The Influence of Admixture on Biological Aging in the Context of Alzheimer’s Disease
This study is looking at how our genes affect aging and the risk of Alzheimer's disease, especially in people whose backgrounds haven't been studied much before, and by joining in, you can help find new ways to understand and possibly prevent Alzheimer's based on your unique genetics.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10996756 on NIH RePORTER |
What this research studies
This research investigates how genetic diversity influences biological aging, particularly in relation to Alzheimer's disease. It focuses on developing and validating methylation clocks, which are tools that measure biological age based on genetic markers, in genetically diverse populations that have been historically underrepresented in research. By understanding these relationships, the study aims to identify potential biomarkers that could predict Alzheimer's risk and inform targeted therapies. Patients participating in this research may contribute to a better understanding of how their unique genetic backgrounds affect their aging process and Alzheimer's disease risk.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals from genetically diverse backgrounds who are at risk for Alzheimer's disease.
Not a fit: Patients who do not have a genetic predisposition to Alzheimer's disease or those who are not from diverse genetic backgrounds may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate predictive tools for Alzheimer's disease risk tailored to diverse populations.
How similar studies have performed: Previous research has shown promise in using methylation clocks as biomarkers for aging and disease risk, but this specific approach in genetically diverse populations is novel.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Cruz Gonzalez, Sebastian — University of California, San Francisco
- Study coordinator: Cruz Gonzalez, Sebastian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.